Management
Senior Leadership Team
Angela Ahmad
General Counsel
Angela has over 20 years of public company legal experience. Prior to joining Inari, Angela served as the Deputy General Counsel of CoreLogic, Inc., where she held various roles including overseeing the corporate governance, M&A and securities functions. Angela also served as a senior associate at Latham & Watkins, LLP and Fried Frank, where she advised clients on corporate transactions, including equity and debt financings. Her private practice experience included five years in London, England during which time she advised corporate and investment banking clients on financing transactions. She earned a BA in French from Stetson University and a JD from the University of Florida.
Tim Benner
Senior Vice President of Sales
Tim joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies. Most recently, Tim spearheaded the global launch and commercial execution of Saluda Medical’s disruptive closed-loop neuromodulation platform. Before joining Saluda, Tim was the Global GM and SVP of Terumo’s Blood and Cell Technologies business. Prior to joining Terumo, Tim was responsible for commercial leadership of the U.S. Structural Heart business at Abbott and oversaw the execution of hyper-growth therapies such as MitraClip, Amulet, and Portico. Tim joined Abbott after approximately 10 years at Edwards Lifesciences where he oversaw several functions across Global Marketing, Commercial Operations, Global Strategy, and Business Development. Tim also worked in a commercial capacity with Endologix, as well as Honda Motor. At Honda, he worked in R&D and spearheaded Advanced Product Development initiatives.
Shon Chakrabarti, MD MPH
Chief Medical Officer, LimFlow
Dr. Shon Chakrabarti first joined Inari Medical in 2021 with an extensive background in patient care, clinical research, and innovation including multiple roles in industry. He completed his residency training at the University of Michigan in 2009 and General and Interventional Cardiology fellowships at the Beth Israel Deaconess Medical Center – Harvard Medical School in 2014, with a master’s degree in Clinical Effectiveness from the Harvard School of Public Health. Following Fellowship, Shon provided front-line Interventional Cardiology care for patients in Southern Virginia. Dr. Chakrabarti’s first industry role was with Abiomed, where he served as Director of Clinical Research and Medical Affairs and provided medical leadership across the Abiomed Clinical Trial Platform. During his time at Inari Medical, Dr. Chakrabarti first served as Vice President, Medical Affairs, providing cross-functional expertise across departments, before taking a role as VP and General Manager, Chronic Venous Therapies and building a national market development team to identify and improve outcomes for patients suffering from chronic venous disease. As CMO of LimFlow, Dr. Chakrabarti will continue to lead an important function and business unit for Inari, focused on improving outcomes for Chronic Limb Threatening Ischemia (CLTI) patients with a novel, breakthrough therapy.
Tara Dunn
Senior Vice President & General Manager, LimFlow
Tara joined Inari in 2016 with executive responsibilities spanning marketing, clinical, regulatory, and quality. Recently, Tara was appointed the General Manager of LimFlow, Inari’s first acquisition and business unit. Prior to Inari, Tara helped establish Volcano Corporation's (acquired by Philips) peripheral business unit where she led the Venous Business Segment. Before Volcano, Tara was in Corporate Development at Medtronic working on a range of transactions including the divestiture of its Physio-Control business unit and the acquisition of China-based Kanghui Holdings. Before Medtronic, Tara's background spanned various roles at Health Advances, a healthcare strategy consulting firm and at InfraReDx, a start-up (acquired by Nipro). Tara earned an AB in Biology from Harvard University, an MS in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy, and an MBA from Harvard Business School. Tara was a member of Harvard's National Championship-winning ice hockey and Ivy League championship-winning softball teams. She also competed in the National Women’s Hockey League (NWHL) for two seasons.
Mitch Hill
Chief Financial Officer
Mitch has extensive experience leading financial functions at both large and small companies. With senior executive experience at a number of private equity and venture capital-backed companies in medical device and health care services, Mitch has led many organizations to scale their financial strategies during rapid growth, such as Cameron Health which was acquired by BSX and Visiogen which was acquired by ABT. Prior to entering the health care industry, served as CFO of Walt Disney Imagineering and as President and CFO of Buy.com, Inc., including at the time of its initial public offering in February 2000. Mitch brings a wealth of financial knowledge and experience from high growth industries and an understanding of the challenges and landscape of modern healthcare. He earned a BS in Accounting from Brigham Young Univ. and an MBA from Harvard Business School.
Drew Hykes
Chief Executive Officer
Drew Hykes has served as our Chief Executive Officer and President and as a member of our Board since January 2023. Mr. Hykes is a proven medical device operating executive with broad functional, geographic and sector experience. From September 2020 until December 2022, Mr. Hykes served as our Chief Operating Officer leading the day-to-day business operations. From September 2017 to September 2020, he served as our Chief Commercial Officer. From 2012 to 2016 Mr. Hykes served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market. Prior to Sequent, Mr. Hykes spent 11 years at Medtronic. His roles at Medtronic included the VP of Marketing for the AF Solutions business, VP of Clinical and Regulatory for the AF Solutions business and Director of Investor Relations. Mr. Hykes also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. Mr. Hykes holds a B.B.A. in Finance from the University of Wisconsin and an MBA from Harvard Business School.
Eric Khairy
Senior Vice President of Marketing
Eric holds over 15 years of medical device experience in marketing, sales, strategy, and product development. Following the acquisition of Volcano by Philips in 2016, Eric progressed from leading global peripheral venous marketing to driving strategy of the peripheral vascular segment at Philips Image-Guided Therapy Devices. Joining Corindus Vascular Robotics in the company’s pre-commercial phase in 2012, Eric launched the first FDA cleared robotic-assisted system for percutaneous coronary interventions. Prior to Corindus, Eric led Intuitive Surgical’s launch and distribution of the da Vinci Surgical System in the Canadian market at Minogue Medical. Eric earned a B.Eng. in computer engineering from McGill University, an M.A.Sc. in biomedical engineering from the University of Montreal, and an MBA from the Sloan School of Management at MIT.
Paul Koehn
Senior Vice President of Operations
Paul brings to Inari over 25 years of experience in high volume, high quality growth operations across multiple industries. With experience both in domestic and global strategic planning, Paul’s work in product development and production has resulted in 4 revolutionary device platforms and 150 total products. Paul has a excellent track record in overall business performance exceeding 80% gross margin on all products, 92% gross margin on devices, and established scalable production and distribution capacity to greater than 4 times demand. In addition, Paul also brings a understanding of construction of manufacturing facilities and corporate offices. Paul was most recently the Senior Vice President of Quality and Operations at Cardiovascular Systems Inc. where he was crucial in the growth of the company from $0 revenue in 2007 to over $200M in 2017.
Andrew Niekamp, MD
Vice President of Medical Affairs
Prior to joining Inari, Dr. Niekamp was a Vascular Interventional Radiologist with Radiology Associates of South Florida and joined the group in July of 2020. He also practiced at Baptist Hospital of Miami, South Miami Hospital and Doctors Hospital. Dr. Niekamp received his undergraduate degree and medical degree from The Ohio State University and completed his post-graduate training at the University of Texas at Houston/M.D. Anderson Cancer Center. He completed his fellowship in Vascular Interventional Radiology at the Miami Cardiac and Vascular Institute. Following fellowship, he joined the faculty at Miami Cardiac and Vascular Institute and was a practicing attending until March 2024. Dr. Niekamp has been an investigator in multiple clinical research trials and is the author of numerous papers and abstracts. During his time in practice, Dr. Niekamp had a particular focus on treating patients suffering from venous thromboembolism.
Kevin Strange
Senior Vice President of Finance, Accounting, Strategy & Business Development
Kevin brings nearly 20 years of medical device experience in corporate development (M&A and venture capital), strategy, finance, equity research and sales. Most recently, Kevin was the Director of Business Development for the Peripheral Interventions division of Boston Scientific, where he helped transform the business from $1B of annual sales to over $1.7B. Kevin’s deal experience spans multiple acquisitions, divestitures and venture investments. Prior to Boston Scientific, Kevin worked as an equity research analyst at Wells Fargo Securities and Bank of America Merrill Lynch covering the MedTech sector. Kevin started his career in medical devices in the Cardiac Rhythm Management division of Medtronic. Kevin holds a BS in Biology from Davidson College and an MBA from New York University’s Stern School of Business.
Brian Strauss
Senior Vice President of Engineering
Brian joined Inari in April 2017. Brian has an extensive background in development of novel and disruptive medical device technologies in early stage companies, consistently resulting in value creation and successful exits. He has held senior executive positions in R&D, operations, and IP development. Prior to joining Inari, Brian was Chief Technology Officer at Reverse Medical, Inc. where he was responsible for developing neurovascular catheters and devices, one of which was sold to Covidien in 2012, the others of which were sold to Medtronic as part of their acquisition of Reverse in 2014. Brian remained at Medtronic as R&D Director of their neurovascular division responsible for embolization product development. Before Reverse Medical, Brian held management and engineering positions at ev3 (acquired by Covidien), Micro Therapeutics (acquired by ev3), and Gish Biomedical (acquired by Sorin Medical). Brian holds a B.S. in mechanical engineering from the University of California, Santa Barbara, and a Masters of Business Administration from California State University, Long Beach. Brian is a named inventor on over 50 issued U.S. and international patents.
Vic Tapson, MD
Vice President of Medical Affairs
Dr. Tapson became interested in acute DVT/PE in the early 1990s, with his earliest research in catheter-directed PE therapy and MR imaging of acute and chronic DVT. He continued with research in all areas of acute VTE, and at the same time, co-funded the Duke Lung Transplant and Duke Pulmonary Hypertension Programs. He enrolled patients in ICOPER in 1990s, and served as PI for a number of national and international PE trials and registries including IMPROVE, NABOR, ENDORSE, OPTALYSE PE, the TAFI inhibitor trial and the BiO2 Angel catheter trial. He served as co-PI for DVT-FREE, the FLARE trial, and many others. After joining Inari, he stepped down from the executive committee for HI PEITHO and Thrombolex trials. He has seen either inpatients or outpatients with acute or chronic PE as well as pulmonary hypertension patients almost daily for decades. He ran Covid trials at Cedars during the pandemic. He was elected to the Royal College of Physicians in 2010. Dr. Tapson has lectured on PE in more than 50 countries.
Tom Tu, MD
Chief Medical Officer
Dr. Thomas Tu joins Inari Medical after practicing Interventional Cardiology for 16 years. He is a graduate of Harvard Medical School and completed residency at Massachusetts General Hospital. He was trained in Interventional Cardiology, Peripheral Vascular Intervention, and Structural Heart Disease at Beth Israel Deaconess Medical Center. Most recently, he was the Cath Lab director and leader of the Pulmonary Embolism, complex PCI, and TAVR programs at Baptist Health Louisville. Dr. Tu helped develop the early phase technology that allowed Inari Medical to optimize patient outcomes. He also served as the presenter for the FLARE IDE trial of the Inari FlowTriever Retrieval/Aspiration System. This study led to FDA 510 (k) clearance for treatment of pulmonary embolism, the first thrombectomy device cleared for that indication.